Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41 SEK | -6.01% | +12.33% | +56.49% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.43M | Sales 2025 * | 343M 32.13M | Capitalization | 2.59B 243M |
---|---|---|---|---|---|
Net income 2024 * | -735M -68.93M | Net income 2025 * | -712M -66.77M | EV / Sales 2024 * | 12.8 x |
Net Debt 2024 * | 474M 44.45M | Net Debt 2025 * | 733M 68.77M | EV / Sales 2025 * | 9.7 x |
P/E ratio 2024 * |
-3.56
x | P/E ratio 2025 * |
-4.22
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | -6.01% | ||
1 week | +12.33% | ||
Current month | +41.67% | ||
1 month | +47.06% | ||
3 months | +28.77% | ||
6 months | +57.33% | ||
Current year | +56.49% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 41 | -6.01% | 199,969 |
24-05-23 | 43.62 | +3.02% | 269,665 |
24-05-22 | 42.34 | +5.11% | 242,333 |
24-05-21 | 40.28 | +4.19% | 273,944 |
24-05-20 | 38.66 | +5.92% | 163,474 |
Delayed Quote Nasdaq Stockholm, May 24, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+56.49% | 243M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- HNSA Stock